Jump to content

Early Detection for LC one of Times Top 10 for 2007


Recommended Posts


Company run by Iranian-American on Time Magazine's top ten list

Panacea Pharmaceuticals' lung cancer diagnostic test, LC Detectsm, has been named one of Time Magazine's Ten Biggest Medical Breakthroughs of 2007. Panacea is headed by Hossein A. Ghanbari, PhD. Dr. Ghanbari co-founded Panacea and serves as Chairman, CEO & Chief Scientific Officer.

Hossein A. Ghanbari, PhD.

Two other Iranian-Americans are on the Board of Directors of Panacea:

Kasra Ghanbari

Mr. Ghanbari co-founded Panacea, serving as Chief Operating Officer and then President through 2004. Currently, he is Chairman and CEO of VEI Studios, Inc., a multi-media development company.

Mehdi Hatamian, PhD

Dr. Hatamian brings his experience in the engineering and information technology fields to the Company, helping to create a diverse, multi-disciplinary, and cross-technology Board that can draw on a vast array of resources.

Following is the press release on the achievement by Panacea:

Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detectsm, Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007

December 18, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals' lung cancer diagnostic test, LC Detectsm, has been named one of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 (click here). LC Detectsm is a simple blood test to facilitate the identification of lung cancer, even among individuals with early-stage disease. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at www.panacea-labs.com.

Lung cancer accounts for the highest number of cancer deaths worldwide, in both men and women. An estimated 213,380 new cases of cancer involving the lung or bronchus are expected in the U.S. in 2007, accounting for about 15 percent of total cancer diagnoses. An estimated 160,390 deaths, accounting for about 29 percent of all cancer deaths, are expected to occur in 2007. Since 1987, more women have died each year from lung cancer than from breast cancer. Lung cancer was the third most common cancer for men and the fifth most common cancer for women in Japan in 2000. The five-year survival rate for lung cancer is only 15 percent. Survival rates for individuals in whom lung cancer is detected at an early stage while it remains localized are as high as 50 percent. Current screening and detection methods rely on imaging modalities, primarily chest x-ray and CT scanning. However, chest x-ray is not sufficiently sensitive and CT scanning is expensive with only a moderate improvement in sensitivity. Newer tests, such as low-dose spiral computed tomography scans and molecular markers in sputum have not proven to be useful to date.

LC Detectsm measures levels of human aspartyl (asparaginyl) beta;-hydroxylase (HAAH), a cancer molecular marker, in blood. HAAH has been detected by immunohistochemical staining in a broad range of cancers, including lung cancer, and has been shown to be highly specific and absent in adjacent non-affected tissue as well as tissue from cancer-free individuals. In addition, HAAH protein levels in serum have been demonstrated to be highly sensitive and specific for cancer in hundreds of patients with a range of cancer types, including lung cancer. Panacea has found increased levels of HAAH in the serum of 99 percent of patients with lung cancer (n=160), including those with early-stage disease. In individuals not known to have cancer, HAAH was essentially undetectable in serum (n=93, specificity = 91 percent). In a population of 50 smokers not known to have cancer the mean serum HAAH level was 0 ng/ml.

"Recognition by Time Magazine of the importance of early detect of lung cancer using LC Detectsm represents a significant milestone for Panacea, and acknowledgement of the clinical importance of this diagnostic test," cited Hossein Ghanbari, Ph.D., Chairman, CEO and CSO of Panacea Pharmaceuticals, Inc. "Widespread use of LC Detectsm should facilitate detection of lung cancer at an earlier stage when effective treatment has a better chance of saving lives and reducing mortality from the number one cancer worldwide."

About Panacea's Oncology Platform

In addition to PC Detectsm, Panacea offers, CC Detectsm, a diagnostic test to aide in the detection of colo-rectal cancer, LC Detectsm, a diagnostic test to aide in the detection of patients with lung cancer, BC Detectsm, a diagnostic test to aide in the detection of recurrence of breast cancer, and TK Sensesm, which determines whether white blood cells from patients with chronic myelogenous leukemia (CML) are sensitive or resistant to imatinib, the therapy of first choice for CML patients, prior to initiation of therapy. The HAAH serum assay will be further developed as a diagnostic test for other types of cancer.

Panacea is also pursuing the development of antibodies directed against HAAH as novel agents for the treatment of cancer with liver cancer as the first therapeutic indication. The Company is exploring both naked anti-HAAH antibodies as well as HAAH antibodies conjugated to chemotherapeutic agents and toxins. PAN-622 is an all-human sequence anti-HAAH monoclonal antibody that has demonstrated excellent efficacy in animals, and is currently in development as a cancer therapeutic.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company's product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies. Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.

Additional information about the Company is available at www.PanaceaPharma.com.

Except for historical information presented in this press release, matters discussed herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the opinions and estimates of management only as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to our access to capital, the progress, costs, and results of any clinical trials undertaken by us, progress of our research and development projects, and uncertainties related to whether our product candidates would ultimately achieve commercial success. We do not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.


Panacea Pharmaceuticals, Inc.

Stephen N. Keith, MD, MSPH

President & COO

Phone 240-243-8000; FAX 240-465


... Payvand News - 12/27/07 ...

Link to comment
Share on other sites

Thanks for the report on this hopeful discovery. The test can already be purchased privately. This is good.

What about access to the test for low income high risk people? Is there a plan and strategy to obtain FDA approval/insurance reimbursement? Is the company working on this? how? coverage for medical interventions based upon the results of this test? There are many accessibility questions and issues. This discovery is an example of where the discovering pharmaceutical and patient/advocates might work together to insure speedy and broad access to this discovery. Do we assume that NCI/FDA are being responsive to this discovery?

There is the initial challenge of discovery and then there is the challenge of access, approval, reimbursement, etc. Advocates might make a difference in how soon there is access and utilization. Hank

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.